Functional Characterization of the Site Specific Residues in Mutacin 1140
Functional Characterization of the Site Specific Residues in Mutacin 1140
批准号:
7920566
负责人:
James Leif Smith
金额:
$3.43万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-22 至 2010-05-31
关键词:
AddressAmino Acid SequenceAntibiotic ResistanceAntibioticsAntimicrobial ResistanceAttentionBacteriaBindingCell WallCell divisionChemistryClinical TreatmentComplexDevelopmentElementsEnterococcus faecalisFamilyFermentationGenesGenetic IdentityGoalsGram-Positive BacteriaGrowthInfectionKnowledgeLipidsLocationMethodsModificationMulti-Drug ResistanceMutagenesisMutationPeptide AntibioticsPeptidoglycanPost-Translational Protein ProcessingProceduresPropertyProteinsReportingResearchResistanceSeriesSeveritiesSiteSite-Directed MutagenesisStaphylococcus aureusStreptococcus mutansStructureTechniquesTestingTherapeutic AgentsThin Layer ChromatographyTimeTransmission Electron MicroscopyVancomycinVariantanalogantimicrobialantimicrobial peptidebactericidedesigndrug resistant bacteriaexperienceimmunogenicityinterestlanthioninemembermonomermutantnovelpathogenpublic health relevanceresearch studythree dimensional structure
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Antimicrobial resistance is a growing concern worldwide, and the severity of the situation is compounded by the modest pipeline of new antimicrobial products. Many strains of medically important bacteria have become increasingly resistant to antibiotics used in the treatment of clinical infections. This problem will continue to worsen over time, unless new antibiotics are developed soon. Preliminary characterization of mutacin 1140, an antibiotic made by a strain of Streptococcus mutans, suggests that it holds great promise. It is a member of the small, novel class of antibiotics called lantibiotics. It is bactericidal at low concentrations against all Gram positive bacteria which it has been tested, including multidrug resistant Staphylococcus aureus and Enterococcus faecalis. It is also active against some Gram negative pathogens. Among other features that make mutacin 1140 desirable for use as an antibiotic, is that spontaneous mutations to resistance have not been found among several pathogens tested. A novel mechanism of activity for mutacin has been described, in which it binds to lipid II trapping lipid II in a large complex of mutacin monomers that abduct lipid II from bacterial growth zones. These growth zones occur at the site of cell division where lipid II carries the peptidoglycan subunits required for the synthesis of new cell wall. The three dimensional structure of mutacin 1140 has been solved by our group providing an opportunity to make "intellectual choices" for site-directed mutagenesis. Thus the goal of this application is to identify the structural components of the antibiotic that are important for lipid II binding, complex formation, and their associated functions with the post-translational modification machinery. Of interest, would be the design of analogs that contain lipid II binding capability, but have lost the ability to form complexes, as well as analogs that can form complexes, but have lost the ability to bind to lipid II. These types of analogs would further our understanding of the mechanism of activity of mutacin 1140 as it pertains to specific regions in the antibiotic. Each mutant will be scored in this proposal, as they relate to lipid II binding, complex formation, bactericidal activity, and their associated function with the modification machinery. PUBLIC HEALTH RELEVANCE The proposal addresses the need for furthering our understanding of the function of an antimicrobial compound called mutacin 1140. A better understanding of the function of the structural elements of this antibiotic may aid in the development of a new class of antibiotics.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Optimization of the Production of the Lantibiotic Mutacin 1140 in Minimal Media.
在基本培养基中优化羊毛硫抗生素 Mutacin 1140 的生产。
DOI:
10.1016/j.procbio.2010.03.031
发表时间:
2010
期刊:
Process biochemistry (Barking, London, England)
影响因子:
--
作者:
[Neeti,Dahal, Noel,Chaney, Dayna,Ellis, Shi-En,Lu, Leif,Smith]
通讯作者:
Leif,Smith
Medical claims and current applications of the potent echinocandin antifungals.
强效棘白菌素抗真菌药的医学主张和当前应用。
DOI:
10.2174/157489110790112563
发表时间:
2010
期刊:
Recent patents on anti-infective drug discovery
影响因子:
--
作者:
[Smith,Leif, Lu,Shi-En]
通讯作者:
Lu,Shi-En
A Novel Therapeutic Agent for the Treatment of Gram-positive Infections
-
批准号:10078988
-
项目类别:
-
资助金额:$23.31万
-
财政年份:2020
-
负责人:James Leif Smith
-
依托单位:
Preclinical Development of OCF001 for Treatment of Yeast Infections
-
批准号:9898242
-
项目类别:
-
资助金额:$96.55万
-
财政年份:2017
-
负责人:James Leif Smith
-
依托单位:
Lead Compound Discovery from Engineered Analogs of Occidiofungin
-
批准号:9345748
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2017
-
负责人:James Leif Smith
-
依托单位:
Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin
-
批准号:9139347
-
项目类别:
-
资助金额:$29.54万
-
财政年份:2016
-
负责人:James Leif Smith
-
依托单位:
Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin
-
批准号:9242586
-
项目类别:
-
资助金额:$23.42万
-
财政年份:2016
-
负责人:James Leif Smith
-
依托单位:
海外基金